Aspirin Should Generally NOT Be Held Before Procedures in Patients with Established CAD
In patients with established coronary artery disease on low-dose aspirin (81 mg daily), aspirin should be continued perioperatively for most procedures, as the cardiovascular risks of discontinuation typically outweigh the bleeding risks. 1
Key Principles for Aspirin Management
Continue Aspirin for Most Procedures
The evidence strongly supports continuation of aspirin through the perioperative period for patients with established CAD:
- Aspirin withdrawal precedes up to 10.2% of acute cardiovascular syndromes, with events occurring at a median of 8.5 days after discontinuation for acute coronary syndromes 2
- Aspirin increases bleeding frequency by only 1.5-fold but does not increase the severity of bleeding complications in most surgeries 2
- The 2007 ACC/AHA perioperative guidelines state that "monotherapy with aspirin need not be routinely discontinued for elective noncardiac surgery" 1
Specific Scenarios Requiring Aspirin Continuation
Class I recommendations (must continue):
- Patients with prior coronary stent placement (especially drug-eluting stents) 1, 3
- Patients undergoing cardiac surgery (CABG) - aspirin should be given preoperatively and continued indefinitely 4
- Patients with recent acute coronary syndrome 4
- Patients undergoing vascular surgery 1
Rare Exceptions Where Holding May Be Considered
Only consider discontinuing aspirin 5-7 days before:
- Intracranial neurosurgery 1, 2
- Transurethral prostatectomy 2
- Procedures where even minor bleeding could cause catastrophic consequences
Critical caveat: Even in these high-risk bleeding scenarios, the decision must weigh the patient's specific cardiovascular risk profile. Patients with recent stents, recent ACS, or high-risk coronary anatomy may still benefit from continued aspirin despite bleeding concerns.
Optimal Aspirin Dosing
Maintain 81 mg (75-100 mg) daily as the standard dose 5, 6:
- This dose provides maximal platelet inhibition with minimal bleeding risk
- Higher doses (325 mg) increase bleeding without improving efficacy 6
- The 2025 ACC/AHA guidelines specifically recommend 75-100 mg daily maintenance 5
Management Algorithm
For elective procedures:
- Default position: Continue aspirin 81 mg daily through the perioperative period
- Assess bleeding risk: Only for intracranial surgery or prostatectomy consider holding
- If holding aspirin: Stop 5-7 days preoperatively and restart within 24 hours postoperatively 1
- Never hold without cardiology consultation if patient has:
- Coronary stent placed within past year
- Recent ACS (within 12 months)
- Left main disease or multivessel CAD
For urgent/emergency procedures:
- Continue aspirin regardless of bleeding risk 1
- The acute cardiovascular risk outweighs bleeding concerns
Common Pitfalls to Avoid
- Do not reflexively hold aspirin based on surgeon preference alone - this requires risk-benefit analysis
- Do not confuse aspirin management with P2Y12 inhibitor management - clopidogrel/ticagrelor have different holding requirements (5-7 days) 4
- Do not restart aspirin late - if held, resume within 24 hours postoperatively 1
- Do not use enteric-coated aspirin perioperatively - non-enteric formulations provide faster antiplatelet effect 4
Special Populations
Patients on dual antiplatelet therapy (DAPT):
- Continue aspirin even if P2Y12 inhibitor must be held 3
- For elective surgery after stent placement: delay surgery until minimum DAPT duration completed (30 days for bare-metal stents, 365 days for drug-eluting stents) 3
Patients on anticoagulation plus aspirin:
- Recent evidence suggests harm from adding aspirin to anticoagulation in stable CAD patients 7
- However, this applies to chronic stable patients, not perioperative management
The overarching principle: aspirin continuation is the default for CAD patients undergoing procedures, with discontinuation reserved only for the highest bleeding-risk surgeries after careful cardiovascular risk assessment.